The Specialty Pharmacy Review Board - Assessing the Value of Novel Therapies and Care Management Strategies for Multiple Sclerosis
Specialty Pharmacy Satellite Dinner Symposium
The Specialty Pharmacy Review BoardTM - Assessing the Value of Novel Therapies and Care Management Strategies for Multiple Sclerosis


Jointly provided by Medical Education Resources, Inc. and Impact Education, LLC.
Impact Education, LLC     Medical Education Resources, Inc.
This activity is supported by an independent educational grant from Novartis Pharmaceuticals Corporation.
Monday, March 27, 2017
6:00 PM - 8:00 PM
Colorado Convention Center
Room 603-607
Denver, CO


Please note: No additional fee is required to attend this CME/CPE activity; however, registration to the AMCP Managed Care & Specialty Pharmacy Annual Meeting 2017 is required.
Held in conjunction with

AMCP Managed Care & Specialty Pharmacy Annual Meeting 2017.

Click here to download the slides from this symposium.

  Review Board Topics Include
  • Profiles of recently approved and emerging therapies for offsetting drug acquisition costs via specific clinical benefits
  • Quality standards, health care policy, and benefit designs to enhance outcomes
  • Care management strategies to boost adherence to treatment plans
  • Current evidence-based diagnosis and treatment data to optimize clinical outcomes
  REVIEW BOARD FACULTY
James Kenney, Jr., RPh, MBA
Manager, Specialty and Pharmacy Contracts
Harvard Pilgrim Health Care
Scott Newsome, DO, MSCS
Director, Neurology Outpatient Services
Director, Neurology Infusion Center
Division of Neuroimmunology and Neuroinfectious Diseases
Johns Hopkins School of Medicine
Kenneth Schaecher, MD, FACP, CPC
Medical Director
Select Health
Fadia Tohme-Shaya, PhD, MPH
Professor and Vice Chair for Academic Affairs
University of Maryland School of Pharmacy
  WHO SHOULD ATTEND?

This activity is designed to meet the educational needs of managed care specialty pharmacists, pharmacy directors, clinical pharmacists, quality directors, medical directors, members of AMCP, and other managed health care professionals attending AMCP Managed Care & Specialty Pharmacy Annual Meeting 2017.

  STATEMENT OF NEED / PROGRAM OVERVIEW

Multiple sclerosis (MS) is a complex disease that requires a collaborative approach to care to achieve optimal patient care and outcomes. Disease-modifying therapies (DMTs) are a core component of MS management. Given current constraints on health care expenditures, the relative cost-effectiveness of these therapies needs to be considered when making treatment decisions. Due to a lack of head to head trials it is difficult to determine which therapy would be most effective for MS; however, it is possible to evaluate current therapies based on their effects on sustained disability, relapse rate, lesion load, brain atrophy, and cognitive dysfunction. Members of the clinical team, as well as patients, need to coordinate these efforts when choosing the appropriate therapy and continually monitor the disease, manage symptoms and the psychological aspects of the disease, and engage the patient through coordinated patient education in order to achieve optimal clinical, economic, and humanistic outcomes. Therefore, it is important for specialty pharmacists and managed care professionals to be aware of and engaged in the care and treatment of MS patients. This symposium will provide an update on available treatments, best practices in care coordination among multiple stakeholders, and benefit design considerations to optimize patient outcomes.

The educational format of The Specialty Pharmacy Review BoardTM will feature a multi-specialty, multi-professional faculty that collaborate, under the leadership of an Activity Chair, on the review of the clinical data, current guidelines, and economic data of a class of therapeutics. Similar to a mock pharmacy and therapeutics committee format, the program will include time for peer-to-peer discussion and debate among the diverse group of faculty members and the audience.

  EDUCATIONAL OBJECTIVES

At the conclusion of this activity, participants should be able to demonstrate improved ability to:
  • Apply current evidence-based diagnosis and treatment data to optimize clinical outcomes for patients with MS in a managed care setting
  • Evaluate quality standards, health care policy, and benefit designs to enhance clinical and economic outcomes for patients with MS
  • Employ care management strategies to boost adherence to treatment plans and improve overall care coordination for MS
  • Provide accurate and appropriate counsel as part of the managed care treatment team
  AGENDA

Date and Time
Monday, March 27, 2017
6:00 PM - 8:00 PM
Colorado Convention Center
Room 603-607
Denver, CO

6:00 PM Dinner and Registration
6:10 PM Pre-Activity Learning Assessment and Opening Comments
James Kenney, Jr., RPh, MBA
6:15 PM Clinical Benefits Overview - Assessing the Clinical Benefits of MS Therapies in a Managed Care Setting
Scott Newsome, DO, MSCS
6:40 PM Practice Guidelines Review - Current Practice Guidelines Review
Kenneth L. Schaecher, MD, FACP, CPC
7:00 PM Health Economics and Pharmacoeconomics Assessment - Analyzing the Available Data to Assess the Value of Treatment Options
Fadia Tohme-Shaya, PhD, MPH
7:20 PM Comparator Treatment Analysis - Comparative Analyses for Evidence- Based Treatment and Benefit Design Decision Making

Benefit Design and Specialty Pharmacy Management Services - Maximizing Value for Current and Emerging MS Therapies
James Kenney, Jr., RPh, MBA
7:45 PM Audience Question and Answer Session
Closing Commentary
Post-Test Assessment

8:00 PM Adjournment
  ACCREDITATION INFORMATION
Physician Continuing Medical Education
Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medical Education Resources, Inc. (MER) and Impact Education, LLC. MER is accredited by the ACCME to provide continuing medical education for physicians.

Medical Education Resources, Inc. designates this live activity for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Continuing Education
Accreditation Statement
Medical Education Resources, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
Medical Education Resources, Inc. designates this continuing education activity for 2.0 contact hours (0.20 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - 0816-9999-17-077-L01-P

Type of Activity: Knowledge


Disclosure of Conflicts of Interest
It is the policy of Medical Education Resources, Inc. to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis.

Americans with Disabilities Act
Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Impact Education, LLC, prior to the live event at (215) 619-8812.

Fee Information
No additional fee is required to attend this CPE/CME activity.

Please note: No additional fee is required to attend this CPE/CME activity; however, registration to the AMCP Managed Care & Specialty Pharmacy Annual Meeting 2017 is required.

Pre-registration will close at 12:00 pm on March 26, 2017.
Walk-in registration will be available at the time of the program.
If you have any questions, please call (215) 619-8812 or email info@impactedu.net.